Hormonal
Tirzepatide (5-15 mg subcutaneous once weekly) produces substantial body weight reduction (up to 21%) in adults with or without type 2 diabetes, with efficacy superior to GLP-1 mono-agonists like semaglutide.
Tirzepatide is a highly effective, once-weekly subcutaneous injection for weight loss, approved for adults with obesity or overweight with weight-related conditions. It works by mimicking hormones (GLP-1 and GIP) that regulate appetite and blood sugar. Clinical trials show significant weight loss (up to 21%) in people without diabetes and up to 15% in those with type 2 diabetes. Common side effects like nausea and diarrhea are usually temporary and can be managed by starting with a low dose and increasing gradually. It is superior to older GLP-1 medications in weight reduction.
In these two trial programs, tirzepatide in doses of 5 mg to 15 mg administered subcutaneously once weekly resulted in body weight reduction of up to 15% in participants with T2D and up to 21% in participants without T2D... The higher weight-reducing efficacy of tirzepatide in trial participants without T2D is currently unexplained... The weight reducing effects of tirzepatide hold great promise for weight management in obese patients regardless of the presence of T2D.
Why this rating
Based on multiple large-scale, randomized, double-blind, placebo-controlled Phase 3 clinical trials (SURMOUNT-1, SURMOUNT-2, SURPASS-1, etc.).
Source
The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
Thomas Leth Jensen et al. · Patient Preference and Adherence · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →